News | April 29, 2025
Pfizer Q1 2025 revenue drops 8% to $13.7 billion
Delivers robust earnings performance, successfully navigating a dynamic environment
Delivers robust earnings performance, successfully navigating a dynamic environment
Akums and TNAU will collaborate to strengthen research through shared expertise and innovative agricultural solutions, to foster innovation in formulation development
DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care
Over 1500 stakeholders representing food businesses, packaging industries, recycling associations, regulatory bodies, environmental organizations, consumer groups, farmer groups, government departments participated in the consultation
Rising demands and advancements in eye care drive growth
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
The company offers customized formulations tailored to align with each brand’s identity and consumer needs
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
The acquisition of MDxK further strengthens the Business Unit’s position in the molecular diagnostics market
The freshly infused capital will primarily be deployed towards expansion and research & development
Subscribe To Our Newsletter & Stay Updated
